Abstract
Retransplant patients are an immunologically unique group since they have already experienced graft loss and have been exposed to a bolus of alloantigen. Having previously lost a transplant, these patients are often sensitized and have poorer early graft function resulting in patient management problems [1, 2]. Survival rates for cadaveric retransplantations have been consistently lower than those for primary grafts [3–6]. Some of the risk factors associated. with poor retransplantation outcome include patient high PRA, recipient-donor HLA mismatches, positive flow cytometry crossmatches and, perhaps the most important, previous graft survival time less than 3–6 months [3, 4, [7–9]. Since the introduction of cyclosporine based immunosuppressive protocols in 1983, the one year regraft survival rate of second cadaver donor renal allografts has remained relatively constant, whereas that of first transplants has significantly improved [9]. However, since 1988 survival rates for retransplant cadaver-donor grafts have improved each year with the difference between first and second transplant one year survival rates decreasing from 8% in 1988 to 2% in 1991 [10]. These recent improvements may reflect the impact of more efficacious immunosuppression and more sensitive and informative crossmatching [6, 11]. However, data from the UNOS Registry suggests that a decreasing number of high-risk patients, especially reTx patients with short previous graft survival times, have been retransplanted in recent years and that selection of more low-risk reTx candidates may be an important contributing factor in explaining improved regraft survivals [8].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Cecka JM, Cho L. Sensitization. In: Terasaki PI (ed.), Clinical Transplants 1988. Los Angeles, UCLA Tissue Typing Laboratory, 1989; 365–373.
Braun WE. Laboratory and clinical management of the highly sensitized organ transplant recipient. Hum. Immunol. 1989; 26: 245–260.
Perdue ST. Risk factors for second transplants. In: Terasaki PI (ed.), Clinical Transplants 1985. Los Angeles, UCLA Tissue Typing Laboratory, 1985; 191–203.
Almond PS, Matas AJ, Gillingham K et al. Risk factors for second renal allografts. Transplantation 1991; 52: 253–258.
Kerman RH, Van Buren CT, Lewis RM et al. Improved graft survival for flow cytometry and anti-human globulin crossmatch negative retransplant recipients. Transplantation 1990; 49: 52–56.
Kerman RH, Kimball PM, Van Buren CT et al. AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival. Transplantation 1991; 51: 316–320.
Cabacungan C. Regrafts. In: Terasaki PI, Cecka JM (eds.), Clinical Transplants 1992, Los Angeles, UCLA Tissue Typing Laboratory, 1993, 347–356.
Cho YW, Cecka JM. Cadaver-donor renal retransplants. In: Terasaki PI, Cecka JM (eds.), Clinical Transplants 1993, Los Angeles, UCLA Tissue Typing Laboratory, 1994, 469–484.
Ogura K, Cecka JM. Cadaver retransplants. In: Terasaki PI (ed.), Clinical Transplants 1990. Los Angeles, UCLA Tissue typing Laboratory, 1991, 471–483.
Mitsuishi Y, Cecka JM. Cadaver retransplants. In: Terasaki PI, Cecka JM. (eds.), Clinical Transplants 1991. Los Angeles, UCLA Tissue Typing Laboratory, 1992, 281–291.
Cook DJ, Terasaki PI, Terashita GY et al. An approach to reducing early transplant failure by flow cytometry crossmatching. Clin. Transplant. 1987; 1: 253–256.
Kahan BD, Van Buren CT, Lin SN et al. Immunopharmacological monitoring of CsA-treated kidney recipients. Transplantation 1982; 34: 36–45.
Kahan BD, Grevel J. Overview-optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631–644.
Kahan BD, Welsh M, Rutzky L et al. The ability of pretransplant test dose pharmacokinetics to reduce early adverse events after renal transplantation. Transplantation 1992; 53: 345–351.
Terasaki PI, Bernoco D, Park MS et al. Microdroplet testing for HLA A, B, C and D antigens. Am. J. Clin. Pathol. 1978; 69: 103–120.
Johnson AH, Rossen RD, Butler WT. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: identification of low levels of preformed antibodies in accelerated allo-graft rejection. Tissue Antigens 1972; 2: 215–226.
Barger BO, Shroyer SL, Hudson MH et al. Successful renal allografts in recipients with a positive standard, DTE negative crossmatch. Transplant. Proc. 1989; 21: 746–747.
Garovoy MR, Rheinschmidt MA, Bigos M et al. Flow cytometry analysis: a high technology crossmatch technique facilitating transplantation. Transplant. Proc. 1983; 15: 1939–1944.
Garovoy MR. Flow cytometry crossmatch testing in renal transplantation. Transplant. Immunol. Lett. 1985; 5: 1–4.
Merrele N, Schulman LE. Determination or prognosis in chronic disease. J. Chronic Dis. 1955; 1: 12–18.
Mann H, Whitney D. On a test of whether one of two random variables is stochastically larger than the other. Ann. Math. Statis. 1947; 18: 50–59.
Scornik JC, Brunson ME, Schaub B et al. The crossmatch in renal transplantation: Evaluation of flow cytometry as a replacement for standard cytotoxicity. Transplantation 1994; 57: 621–625.
Ogura K, Terasaki PI, Johnson C et al. The significance of a positive flow cytometry crossmatch test in primary kidney transplantation. Transplantation 1993; 56: 294–298.
Rights and permissions
Copyright information
© 1997 Kluwer Academic Publishers
About this chapter
Cite this chapter
Kerman, R.H. et al. (1997). Retransplantation following AHG-negative crossmatches. In: Retransplantation. Transplantation and Clinical Immunology, vol 29. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-38142-8_20
Download citation
DOI: https://doi.org/10.1007/978-0-585-38142-8_20
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-4937-2
Online ISBN: 978-0-585-38142-8
eBook Packages: Springer Book Archive